Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.44 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506371 | 0.83 | MEN1 (0.52) | TBXA2RPOLBAPEX1MEN1KMT2A | |
| SCHEMBL30641945 | 0.82 | LRRK2 (0.51) | LRRK2EPHX2POLBMEN1KMT2A | |
| SCHEMBL20787533 | 0.82 | LRRK2 (0.51) | LRRK2EPHX2POLBMEN1KMT2A | |
| SCHEMBL26019644 | 0.79 | LRRK2 (0.42) | LRRK2SSTR4EPHX2 | |
| SCHEMBL4926140 | 0.78 | SMN1; SMN2 (0.51) | POLBAPEX1KMT2AALDH1A1 | |
| SCHEMBL507273 | 0.78 | EPHX2 (0.55) | ANO1MAOAMAOBEPHX2POLB | |
| SCHEMBL13161980 | 0.77 | CNR1 (0.53) | LRRK2SSTR4EPHX2EGLN1 | |
| SCHEMBL13634462 | 0.77 | CNR1 (0.44) | LRRK2SSTR4EPHX2MEN1KMT2A | |
| SCHEMBL3361866 | 0.76 | LRRK2 (0.48) | LRRK2MEN1KMT2AALDH1A1PKM | |
| SCHEMBL289026 | 0.76 | XDH (0.49) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | LRRK2 1385/4885TBXA2R 2049/4885ANO1 1500/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | LRRK2 1125/4885TBXA2R 2934/4885ANO1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.